The overall goal of this Program Project is to develop an HIV vaccine strategy based on the HSV -1 amplicon vector, and to test this approach in small animal and large animal models. We will test the HSV amplicon vector alone and in combination with a DNA vaccine provided by the NIAID Vaccine Research Center (VRC). We propose 3 Projects. In Project by Dewhurst, """"""""Immunogenicity of HSV amplicon vectors in small animals"""""""", we will carry out studies in mice and guinea pigs to examine: 1) amplicons delivered mucosally, 2) their interaction with dendritic cells, 3) multigene SIV amplicon constructs, 4) a prime-boost experiment with a matching DNA vaccine, and 5) molecular adjuvants. In Project by Lewis, """"""""Immunogenicity of HSV amplicon vectors in rhesus macaques"""""""", we will verify the immunogenicity of the HSV amplicon with SIV gene inserts. Specifically, we will examine amplicon delivery route, dose, multigene construct characteristics and the effect of homologous DNA prime- amplicon boost. Next we will perform a live virus challenge experiment in macaques immunized with the optimal multigenic SIV amplicon preparation with DNA priming. The challenge virus will be a highly pathogenic, molecularly cloned, SIVmac239 for assessment of protection from infection or disease progression. Finally, we will conduct studies to determine the immunogenicity of amplicon vectors encoding multiple HIV-1 clade C antigens (Gag, Tat, Nef, Env), alone or in combination with the VRC DNA prime. This data will allow us to make key decisions concerning a possible future human clinical trial using amplicon-based HIV vaccines. In Project by Federoff, """""""" Amplicon Development and Enhancement"""""""", we will optimize the amplicon technology by: 1) developing a scalable process for high-titer amplicon production using helper virus-based/helper virus-free methods and well-characterized recombinase systems, 2) developing an affinity-based amplicon purification method, and 3) enhancing knowledge of co-packaged and purified protein constituents by proteomic analysis, which may enable the development of improved methods for amplicon production/purification.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
1P01AI056356-01
Application #
6682052
Study Section
Special Emphasis Panel (ZAI1-HSD-A (M2))
Program Officer
Pensiero, Michael N
Project Start
2003-07-15
Project End
2007-12-31
Budget Start
2003-07-15
Budget End
2003-12-31
Support Year
1
Fiscal Year
2003
Total Cost
$1,380,413
Indirect Cost
Name
University of Rochester
Department
Internal Medicine/Medicine
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Azadniv, Mitra; Bowers, William J; Topham, David J et al. (2011) CD4+ T cell effects on CD8+ T cell location defined using bioluminescence. PLoS One 6:e16222
Bimber, Benjamin N; Chugh, Pauline; Giorgi, Elena E et al. (2009) Nef gene evolution from a single transmitted strain in acute SIV infection. Retrovirology 6:57
Burris, Clark A; de Silva, Suresh; Narrow, Wade C et al. (2008) Hexamethylene bisacetamide leads to reduced helper virus-free HSV-1 amplicon expression titers via suppression of ICP0. J Gene Med 10:152-64
Santos, Kathlyn; Duke, Cindy M P; Rodriguez-Colon, Sol M et al. (2007) Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag. Vaccine 25:1634-46
Santos, Kathlyn; Simon, David A L; Conway, Erin et al. (2007) Spatial and temporal expression of herpes simplex virus type 1 amplicon-encoded genes: implications for their use as immunization vectors. Hum Gene Ther 18:93-105
Santos, Kathlyn; Sanfilippo, Christine M; Narrow, Wade C et al. (2007) Infectivity of herpes simplex virus type-1 (HSV-1) amplicon vectors in dendritic cells is determined by the helper virus strain used for packaging. J Virol Methods 145:37-46
Duke, Cindy M P; Maguire, Casey A; Keefer, Michael C et al. (2007) HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime. Vaccine 25:7410-21
Azadniv, Mitra; Dugger, Kari; Bowers, William J et al. (2007) Imaging CD8+ T cell dynamics in vivo using a transgenic luciferase reporter. Int Immunol 19:1165-73
Lankes, H A; Zanghi, C N; Santos, K et al. (2007) In vivo gene delivery and expression by bacteriophage lambda vectors. J Appl Microbiol 102:1337-49
Santos, Kathlyn; Duke, Cindy M P; Dewhurst, Stephen (2006) Amplicons as vaccine vectors. Curr Gene Ther 6:383-92

Showing the most recent 10 out of 11 publications